



ANDA 211182

ANDA TENTATIVE APPROVAL

Hetero USA, Inc.
U.S. Agent for Hetero Labs Limited Unit V
1035 Centennial Avenue
Piscataway, NJ 08854
Attention: Soma Raju
Vice President, Regulatory Affairs

Dear Soma Raju:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on November 13, 2017, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Ibrutinib Capsules, 140 mg.

Reference is also made to the complete response letter issued by this office on August 21, 2024, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. We have determined your Ibrutinib Capsules, 140 mg, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Imbruvica Capsules, 140 mg, of Pharmacyclics LLC (Pharmacyclics) NDA – 205552.

However, we are unable to grant final approval to your ANDA at this time because of the exclusivity issue noted below. Therefore, the ANDA is **tentatively approved**. This determination is based upon information available to the Agency at this time (e.g., information in your ANDA and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacturing and testing of the drug product). This determination is subject to change on the basis of new information that may come to our attention. This letter does not address issues related to the 180-day exclusivity provisions under section 505(j)(5)(B)(iv) of the FD&C Act.

The RLD upon which you have based your ANDA, Pharmacyclics's Imbruvica Capsules, 140 mg, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
7,514,444 (the '444 patent)	June 28, 2027*
8,008,309 (the '309 patent)	May 13, 2028*
8,476,284 (the '284 patent)	June 28, 2027*
8,497,277 (the '277 patent)	June 28, 2027*
8,563,563 (the '563 patent)	October 26, 2027*
8,697,711 (the '711 patent)	June 28, 2027*
8,703,780 (the '780 patent)	June 28, 2027*
8,735,403 (the '403 patent)	June 28, 2027*
8,754,091 (the '091 patent)	June 28, 2027*
8,952,015 (the '015 patent)	June 28, 2027*
8,957,079 (the '079 patent)	June 28, 2027*
8,999,999 (the '999 patent)	December 3, 2031*
9,125,889 (the '889 patent)	December 3, 2031*
9,181,257 (the '257 patent)	June 28, 2027*
9,296,753 (the '753 patent)	April 30, 2034*
9,540,382 (the '382 patent)	February 18, 2034*
9,713,617 (the '617 patent)	December 3, 2033*
9,725,455 (the '455 patent)	December 3, 2033*
9,795,604 (the '604 patent)	April 24, 2035*
9,801,881 (the '881 patent)	December 3, 2031*
9,801,883 (the '883 patent)	December 3, 2031*
10,004,746 (the '746 patent)	December 3, 2031*

10,016,435 (the '435 patent)	December 3, 2031*
10,106,548 (the '548 patent)	December 3, 2033*
10,125,140 (the '140 patent)	December 3, 2033*
10,294,231 (the '231 patent)	December 3, 2033*
10,294,232 (the '232 patent)	December 3, 2033*
10,463,668 (the '668 patent)	April 24, 2035*
10,478,439 (the '439 patent)	December 3, 2031*
10,695,350 (the '350 patent)	April 24, 2035*
10,751,342 (the '342 patent)	December 3, 2031*
10,752,634 (the '634 patent)	December 3, 2033*
10,961,251 (the '251 patent)	December 3, 2033*
11,672,803 (the '803 patent)	June 3, 2031

* with pediatric exclusivity added

Your ANDA contains paragraph IV certifications to each of the patents¹ under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Ibrutinib Capsules, 140 mg, under this ANDA. You have notified the Agency that Hetero Labs Limited Unit V (Hetero) complied with the requirements of section 505(j)(2)(B) of the FD&C Act. Litigation was initiated within the statutory 45-day period against Hetero for infringement of the '753, '382, '617, and '455 patents in the United States District Court for the District of Delaware [Pharmacyclics LLC and Janssen Biotech, Inc. v. Hetero USA Inc., Civil Action No. 18-01778]. You have also notified the Agency that this case was dismissed.

The RLD upon which you have based your ANDA, Pharmacyclics's Imbruvica Capsules, 140 mg, is subject to periods of exclusivity. As noted in the Orange Book, the M-14, NPP, and ODE-405 exclusivities are scheduled to expire on August 24, 2025, February 24, 2026 (including attached pediatric exclusivity), and February 24, 2030 (including attached pediatric exclusivity), respectively. Your ANDA contains a statement that you do not seek to market Ibrutinib Capsules, 140 mg, prior to the expiration of these exclusivities. Therefore, final approval cannot be granted until the ODE-405 exclusivity has expired, currently February 24, 2030.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, if your ANDA receives final approval, it may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to: <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

RESUBMISSION

To request final approval, please submit an amendment titled “FINAL APPROVAL REQUESTED” with enough time to permit FDA review prior to the date you believe that your ANDA will be eligible for final approval. A request for final approval that contains no new data, information, or other changes to the ANDA generally requires a period of 3 months for Agency review. Accordingly, such a request for final approval should be submitted no later than 3 months prior to the date on which you seek approval. A request for final approval that contains substantive changes to this ANDA or changes in the status of the manufacturing and testing facilities’ compliance with cGMPs will be classified and reviewed according to OGD policy in effect at the time of receipt. Applicants should review available Agency guidance for industry related to amendments under the generic drug user fee program to determine the duration of Agency review needed to review the changes submitted. As part of this consideration, applicants should monitor any changes to the RLD that occur after tentative approval, including changes in labeling, patent or exclusivity information, or marketing status. The submission of multiple amendments prior to final approval may also result in a delay in the issuance of the final approval letter.

The amendment requesting final approval should provide the legal/regulatory basis for your request for final approval and should include a copy of a court decision, settlement or licensing agreement, or other information described in 21 CFR 314.107, as appropriate. It should also identify changes, if any, in the conditions under which the ANDA was tentatively approved, e.g., updated information such as final-printed labeling, chemistry, manufacturing, and controls data as appropriate. This amendment should be submitted even if none of these changes were made, and it should be designated clearly in your cover letter as a “FINAL APPROVAL REQUESTED.”

In addition to the amendment requested above, the Agency may request, at any time prior to the date of final approval, that you submit an additional amendment containing information as specified by the Agency. Failure to submit either or, if requested, both

types of amendments described above may result in a delay in the issuance of the final approval letter.

This drug product may not be marketed without final Agency approval under section 505(j) of the FD&C Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under section 301 of the FD&C Act. Also, until the Agency issues the final approval letter, this drug product will not be deemed approved for marketing under section 505(j) of the FD&C Act, and will not be listed in the Orange Book. Should you believe that there are grounds for issuing the final approval letter prior to February 24, 2030², you should amend your ANDA accordingly.

For further information on the status of this ANDA or upon submitting an amendment to the ANDA, please contact Dustin DeRosales, Regulatory Project Manager, at (301) 796 - 1950.

Sincerely yours,

{See appended electronic signature page}

For Edward M. Sherwood
Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

¹ The Agency notes that the '563, '746, '435, '548, '140, '231, '232, '668, '439, '350, '342, '634, '251, and '803 patents were submitted to the Agency after submission of your ANDA. Litigation, if any, with respect to these patents would not create a statutory stay of approval.

² We note that this ANDA currently is eligible for approval the day after expiration of the pediatric exclusivity period. See Section 505A(b)(1)(B) of the FD&C Act. If this day falls on a Saturday, Sunday, or Federal holiday, it will be eligible for approval the next business day.



Paul
Levine

Digitally signed by Paul Levine

Date: 2/20/2025 08:27:38AM

GUID: 56323ddc003554a87fad6698c2baa467